Study Summary
This trial is testing a new combination of drugs to treat non-squamous NSCLC that is positive for PD-L1.
- Stage IV Non-small Cell Lung Cancer
- PD-L1 Gene Mutation
- Non-Small Cell Lung Cancer
- Advanced Treatment-Naïve Programmed Death-Ligand 1 (PD-L1)
- Sitravatinib
- Pembrolizumab
- Lung Cancer
- Lung Disease
- Non-Small Cell Lung Cancer (NSCLC)
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
1 Primary · 5 Secondary · Reporting Duration: 2 years
Trial Safety
Phase-Based Safety
Awards & Highlights
Trial Design
4 Treatment Groups
Group 1B: PD-L1 1-49%, Pembrolizumab run-in population
1 of 4
Group 2A: PD-L1 ≥ 50%, Main Study Population
1 of 4
Group 2B: PD-L1 ≥ 50%, Pembrolizumab run-in population
1 of 4
Group 1A: PD-L1 1-49%, Main Study Population
1 of 4
Experimental Treatment
70 Total Participants · 4 Treatment Groups
Primary Treatment: Sitravatinib · No Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 1 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Are there any vacancies remaining in this research protocol?
"Affirmative. According to information accessible on clinicaltrials.gov, this experiment is actively recruiting patients and was initially shared on February 10th 2022 with its most recent update occurring October 26th of the same year. 70 research participants are required from 3 different sites." - Anonymous Online Contributor
How many individuals are currently participating in this clinical experiment?
"Affirmative, clinicaltrials.gov details that this medical study is actively looking to recruit patients since its first posting on February 10th 2022 and latest update on October 26th 2022. 70 individuals must be enrolled at 3 sites for the trial's completion." - Anonymous Online Contributor
Could you provide a summary of the research conducted on Pembrolizumab?
"Currently, there are 975 clinical trials exploring the efficacy of Pembrolizumab treatment. Of these studies, 124 have reached Phase 3 and many of them originate from Houston, Texas. However, there exists a global network with 36150 sites running research for this medication." - Anonymous Online Contributor
How is Pembrolizumab utilized to treat medical conditions?
"Pembrolizumab is typically used to battle malignant neoplasms, although it has also been known to be successful in treating unresectable melanoma, microsatellite instability high, or chemotherapy-resistant diseases." - Anonymous Online Contributor
Has Pembrolizumab been granted sanction by the FDA?
"Our Power team evaluated pembrolizumab's safety as a 2, owing to the fact that Phase 2 data only provide insight into its security profile and not its efficacy." - Anonymous Online Contributor